Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times
Teva and Nuvelution partner on Tourette drug development
Multiple Sclerosis: New Treatments, Tough Decisions
Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much | The Motley Fool
Multiple Sclerosis Drugs Market Size, Growth | Forecast 2027
Blues plan sues Teva over marketing for its MS drug Copaxone
Teva Pharmaceuticals - Wikipedia
EC Investigating Teva for Competing MS Drug
Teva scraps Heptares migraine pact as lead drug nears clinic | Fierce Biotech
Better Late Than Never: Novartis, Momenta Win FDA Approval for Delayed MS Drug | BioSpace
Antitrust Action Targets Teva Multiple Sclerosis Drug | New Jersey Law Journal
Teva 'Plagued By Problems,' Downgraded On Lost MS Drug Patents, DOJ Probe | Stock News & Stock Market Analysis - IBD
Targeted Delivery Platforms for the Treatment of Multiple Sclerosis | Molecular Pharmaceutics
Teva Class Action Claims Company Suppressed Competition For Generic Version Of MS Drug Copaxone - Top Class Actions
BCBS Vermont suing Teva Pharmaceuticals over MS drug marketing | Healthcare Finance News
Teva's COPAXONE Approved in Japan for the Prevention of Relapse Remitting Multiple Sclerosis
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study | Fierce Pharma
![Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)](https://mma.prnewswire.com/media/1019389/Teva_Canada_Limited_Teva_Canada_Announces_the_Launch_of_a_Bioequ.jpg?p=facebook "Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)")
Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Teva sues FDA over bid to block approval of generic Copaxone | Mint
Is Teva doomed after Copaxone's increased competition and Laquinimod's failed Phase III trial? - Pharmaceutical Technology
EU says Teva blocked generics to MS drug Copaxone | pharmaphorum
Multiple sclerosis and drug discovery: A work of translation - eBioMedicine
US states sue Teva for price-fixing in 'multi-billion dollar fraud' | The Times of Israel
